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PTCH1 gene, which is implicated in
susceptibility to different forms of skin
cancer and carries three intronic
variants, one of which affects trans-
cription factor binding. Functional
analysis of the possible roles of these
and other variants in determining the
MSSE phenotype, e.g., by gene
expression or chromatin immuno-
precipitation sequencing analysis to
assess differential transcription factor
binding, will require further studies
using keratinocytes or cultured primary
tumor cells from MSSE-affected patients.
Finally, it is possible that, as loss-of-
function germline mutations in TGFBR1
are very rare, the conserved haplotype
may act as a modifier to increase
survival of individuals carrying strong
mutations in this potent developmental
regulator. This mechanism is supported
by the identification of unlinked variant
genetic modifiers that are preferentially
inherited in mice haploinsufficient for
Tgfb1 (Benzinou et al, 2012).
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TO THE EDITOR
Type VII collagen (C7) is located in the
skin between its two main layers, the
epidermis and the dermis, where it
forms structures, anchoring fibrils (AFs),
which are necessary for epidermal–
dermal adherence (Sakai et al., 1986;
Burgeson, 1993). The COL7A1 gene
encodes for a 290-kDa alpha chain
(Christiano et al., 1994). C7 is com-
posed of three alpha chains that form
a homotrimer of B900 kDa. Within the
extracellular space, C7 molecules form
antiparallel dimers, which aggregate
laterally to form AFs. C7 has some
unusual properties that make it quite
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distinctive from other collagens, such as
its solubility in neutral buffers. Most
skin-associated collagens such as type I
collagen induce platelet aggregation
and clot formation when exposed to
the blood stream, whereas C7 does not
(Saelman et al., 1994).
Defects in both alleles of COL7A1
cause an absence or reduction of func-
tional C7 and AFs, resulting in recessive
dystrophic epidermolysis bullosa
(RDEB). RDEB patients have skin fragi-
lity, skin blistering, erosions, milia for-
mation, nail loss, joint contractures,
fibrotic mitten deformities of the hands
and feet, mutilating scars, esophageal
strictures, and aggressive squamous cell
carcinomas that take the patients’ lives
prematurely (Fine et al., 2008). Unfortu-
nately, RDEB is incurable. Various thera-
peutic strategies have been envisioned
for RDEB based on preclinical animal
models, including the intradermal
injection of allogeneic dermal fibro-
blasts or gene-corrected RDEB fibroblasts
(Ortiz-Urda et al., 2003; Woodley et al.,
2003), intradermal injection of lentiviral
vectors expressing C7 (Woodley et al.,
2004), and transplantation of gene-
corrected keratinocyte autografts (Chen
et al., 2002; Ortiz-Urda et al., 2002).
Recently, proof-of-principle clinical trials
have been initiated in RDEB patients,
including bone marrow/stem cell trans-
plantation and intradermal injection
of allogeneic fibroblasts (Wong et al.,
2008; Wagner et al., 2010). None of
these therapies have proven to be con-
sistently effective.
We demonstrated that the intradermal
injection of human recombinant C7
(rC7) into RDEB skin equivalents grafted
onto immunodeficient mice or into
RDEB-like, C7-knockout mice results in
new C7 and AFs and reverses the RDEB
skin phenotype (Woodley et al., 2004;
Remington et al., 2009). Nevertheless,
intradermally injected rC7 has a small
diffusion radius and is not ideal for
treating large areas of skin in RDEB
patients who usually have widespread
lesions, including the oral cavity and
esophagus. In the present study, we
sought to determine whether we could
ameliorate RDEB by intravenously (IV)
administering rC7. We hypothesized
that IVC7 would simultaneously home
to multiple RDEB wounds and restore
C7 expression and function.
We used two animal models—a full-
thickness skin wound created in athy-
mic nude mice and an RDEB skin
transplantation mouse model. For the
first model, 1 cm by 1 cm full-thickness
wounds were made on the backs of
athymic nude mice. Between 4 and
8 hours later, we injected the tail veins
of the mice with rC7. As shown in
Figure 1a, the IV-injected rC7 homed
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Figure 1. Intravenous (IV)-injected rC7 homes to skin wounds and incorporates into the mouse’s regenerated dermal (d)–epidermal (e) junction (DEJ).
(a) Immunofluorescence staining of mouse skin (after IV injection of 100mg of rC7 or laminin 111) was performed with antibodies specific for human C7 at 2 weeks
after the injection. Note that the IV-injected rC7 (n¼ 20 mice) homed and incorporated into the regenerated DEJ of the healed wound sites (C7-W) but was not
present in unwounded skin sites (C7-UW). No rC7 was detected in mice IV injected with laminin 111 (n¼5 mice) or phosphate-buffered saline (PBS; n¼10 mice)
(L1-W and PBS-W). (b) Dose-dependent deposition of rC7 at the mouse’s DEJ after IV injection with rC7. Immunofluorescence staining with an antibody specific
for human C7 was performed on healed mouse skin wounds 2 weeks after the animals were injected with 30mg rC7, 60mg rC7, or 120mg rC7, as indicated,
respectively. All photographs were taken at the same exposure time.
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to wound sites and incorporated into the
dermal–epidermal junction (DEJ) at 2
weeks after injection. By contrast, there
was no detectable human rC7 in
unwounded skin. None of the mice
injected with PBS (phosphate-buffered
saline) or laminin 111, a large non-
collagenous glycoprotein within base-
ment membranes, had rC7 in their
healed skin. As shown in Figure 1b,
with increasing doses of rC7, we
detected a dose-dependent increase in
rC7 at the mouse’s DEJ. In addition, IV-
injected rC7 was sustained at the
mouse’s DEJ for at least 8 weeks (data
not shown).
We then examined whether IV-
injected rC7 trafficked to other organs.
Human rC7 was only observed in
healed skin wounds and not in
unwounded skin or esophagus, sto-
mach, tongue, small intestine, brain,
kidney, liver, lung, spleen, or heart
(Supplementary Figure S1 online).
Finally, we did not observe any adverse
effects in mice receiving IV rC7 at doses
as high as 33 mg per kg body weight.
Daily weight, activity, and feeding
habits were identical between the
experimental and control groups.
To evaluate intravenous C7 in an
RDEB-like model, we transplanted skin
from C7 knockout mice that have no C7
or AFs in their DEJ (Heinonen et al.,
1999) onto the backs of athymic nude
mice. These newborn, CO7A1-null
mice exhibit extensive skin blisters and
die within the first week of life. These
C7-null mice recapitulate the clinical,
genetic, and ultrastructural features of
RDEB. Because these small neonatal
mice only live for a few days, it is not
technically feasible to inject their tail
veins with C7. As an alternative, we kill
these mice after birth and transplant
their skin onto the backs of adult
athymic, nude mice. As shown in
Figure 2a, RDEB skin grafts before treat-
ment showed histological evidence of
dermal–epidermal separation and
entirely lacked C7 staining at the DEJ,
which is characteristic of RDEB.
Full-thickness skin wounds are very
different from the superficial bullous
wounds of RDEB skin, which occur at
the epidermal–dermal interface. Having
shown that intravenous rC7 homes to
full-thickness skin wounds, we wished
to evaluate whether intravenous rC7
would also home to grafted RDEB
mouse skin wounds. We administered
intravenous rC7 to the adult athymic
nude mice hosting RDEB mouse
skin grafts. As shown in Figure 2a,
IV-injected rC7 homed to the RDEB
mouse skin, incorporated into the DEJ,
and corrected the dermal–epidermal
separation. By contrast, C7-null RDEB-
like skin transplanted onto mice that
received PBS injections revealed
dermal–epidermal separation and had
no rC7. These experiments show that
although the characteristic RDEB wound
is superficial the wound is sufficient
to allow intravenously injected rC7 to
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Figure 2. Intravenous (IV)-injected rC7 incorporates into the dermal–epidermal junction (DEJ) of recessive dystrophic epidermolysis bullosa (RDEB) mouse skin
grafted onto athymic nude mice in vivo. (a) Histological appearance (upper panels) and immunofluorescence staining (lower panels) of engrafted RDEB mouse
skin using a monoclonal antibody specific for human C7. Left panels (Before) are skin biopsies from transplanted RDEB skin grafts taken 2 weeks after
grafting and before treatment (n¼ 30 mice). Middle panels (phosphate-buffered saline (PBS)) are 2-week post-injection biopsies from RDEB skin grafts on athymic
host nude mice that were IV injected with PBS (n¼ 4 mice). Right panels (C7) are 2-week post-injection biopsies from RDEB skin grafts on athymic host nude mice
that were IV injected with 60mg of rC7 (n¼ 9 mice). e, epidermis; d, dermis. (b) Immunogold labeling of engrafted murine RDEB skin injected with PBS or 60mg
rC7 (C7) was performed with an antibody specific to human C7 (NP185, a gift of Dr Lynn Sakai, Shriners Hospital for Children, Portland, Oregon), followed by
a 1-nm gold secondary antibody. Identical immuno-electron microscopy (IEM) was performed on normal mouse skin (NMS). Note that IV-injected rC7
incorporated into the RDEB skin grafts and formed anchoring fibrils (AFs). Note restoration of numerous arching AFs depicted with arrows and labeled with gold
particles decorating the DEJ of RDEB skin grafts that received IV rC7. IEM on NMS shows numerous unlabeled AFs. D, dermis; E, epidermis; HD,
hemidesmosomes; bar¼100 nm.
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home to it, incorporate into the DEJ, and
improve epidermal–dermal adherence.
To determine whether IV rC7 could
restore AFs at the DEJ of the engrafted
RDEB mouse skin in vivo, we carried out
immuno-electron microscopy using a
monoclonal antibody that is specific to
human C7 and recognizes an epitope
within the NC1 domain of C7, as
described (Sakai et al., 1986; Sakai and
Keene, 1994). As shown in Figure 2b, the
injected rC7 incorporated into the DEJ of
the engrafted RDEB mouse skin and
formed AF structures, thus demonstrating
correction of the major ultrastructural
abnormality of RDEB mouse skin. By
contrast, there were no detectable AFs at
the DEJ of RDEB mouse skin grafts trans-
planted onto mice that received intrave-
nous PBS. These data indicate that protein-
based therapy by IV injection of rC7 can
correct the abnormal RDEB dermal–epi-
dermal separation and restore C7 expres-
sion and AF formation at the DEJ in vivo.
In summary, we showed that rC7
administered intravenously to mice
homed to engrafted RDEB mouse skin,
incorporated into the DEJ of the grafts,
and restored C7, AFs, and epidermal–
dermal adherence. These data suggest
that intravenously administered rC7
could simultaneously migrate to the
DEJ throughout the RDEB patient’s skin,
reverse the ‘‘subclinical’’, microscopic
epidermal–dermal separation, and pro-
phylactically prevent frank skin blisters
and erosions from forming. We believe
that protein therapy via intravenous rC7
may be a valid therapeutic strategy for
patients with RDEB who currently have
few therapeutic options.
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